CIC Edizioni Internazionali. Anabolic treatment for osteoporosis: teriparatide. Mini-review
|
|
- Aubrey Stokes
- 5 years ago
- Views:
Transcription
1 Anabolic treatment for osteoporosis: teriparatide Mini-review Richard Eastell Jennifer S. Walsh Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK (R.E., T.V.) Address for correspondence: Prof. Richard Eastell, M.D., F.R.C.P., F.R.C. Path, FMedSci Metabolic Bone Centre, Northern General Hospital Herries Road, Sheffield, South Yorkshire, S5 7AU, UK Phone: +44 (0) ; Fax: +44 (0) Summary Teriparatide is a safe and effective anabolic treatment for osteoporosis. In postmenopausal women, it increases BMD and decreases vertebral fractures by about 70% and non-vertebral fractures by about 45% (although there is no evidence that it prevents hip fractures). The current evidence indicates that it should be administered for a single course of 24 months, and followed with an anti-resorptive agent to maintain the BMD gain. There is no clear benefit to repeated or cyclical treatment. Combination treatment, particularly with denosumab achieves greater BMD increase than either agent alone, but there are no available fracture data for combination treatment. There are some unknowns; most fundamentally why daily PTH administration is anabolic to bone when continuous high PTH is catabolic. Also, a better understanding of why the anabolic action declines with time and why there is a poor response to repeated treatment may help us to use teriparatide more effectively, and increase our understanding of bone biology and osteoporosis pathophysiology. KEY WORDS: bone turnover markers; osteoporosis; bone formation; fracture; bone mineral density; teriparatide. Introduction Teriparatide refers to the molecule that makes up the first 34 amino acids of the intact parathyroid hormone (PTH, 84 amino acids). When PTH is given continuously, it stimulates bone resorption and loss of trabecular bone, as seen in endogenous primary hyperparathyroidism. When it is given intermittently, such as by daily injections, then it is anabolic and increases trabecular bone. It not only increases trabecular connectivity but also cortical thickness, based on microcomputed tomography studies of iliac crest bone biopsies (1). Teriparatide is the only current licensed anabolic treatment for osteoporosis in many countries. In most regions, it is restricted to second-line use as osteoporosis treatment due to greater cost than first-line agents such as alendronate. There is now extensive clinical experience with teriparatide, a good evidence base for its safety and efficacy, and some data on sequential or combination use with other osteoporosis drugs. However, there are still several unknowns around its mechanism of action, and why its anabolic effect decreases with time and repeated treatment. Intact parathyroid hormone has been licenced in Europe, but it is no longer available and so will not be discussed further. Abaloparatide is a modified version of the N-terminal region of parathyroid hormone-related protein that is currently in development for the treatment of osteoporosis but is outside the scope of this article. Indications The approved indications for treatment include the treatment of postmenopausal osteoporosis, male osteoporosis and glucocorticoid-induced osteoporosis. Teriparatide has been reported to improve bone mineral density in other clinical situations, such as osteogenesis imperfecta and anorexia nervosa, but it is not licenced for these indications, and so this is outside the scope of this article. We will focus on postmenopausal osteoporosis, but there is evidence for an increase in bone mineral density in men that is just as great as for women (2). In women and men with glucocorticoid-induced osteoporosis, there is evidence for anabolic effect as assessed by bone turnover markers and bone mineral density and there are fewer vertebral fractures than with treatment with alendronate (3). In the UK, treatment is limited to patients with severe osteoporosis. In women, this means that they must be unable to take alendronate or else have an unsatisfactory response to alendronate (fracture or decrease in bone mineral density despite being compliant with medication for 12 months) (NICE TA161 Also, women over 65 years must have a T-score that is -4 or less or else -3.5 and 3 or more fractures. Women under 65 years must have a T-score of -4 and 3 or more fractures. When we find a poor response to alendronate, we begin by ruling out poor adherence and secondary osteoporosis (such as vitamin D deficiency) and then measure bone turnover markers. If the markers are not suppressed, then we change from alendronate to zoledronic acid (5mg by annual intravenous infusion) or denosumab (60mg 6-monthly by subcutaneous injection). If the bone turnover markers are suppressed, this suggests that despite effective anti-resorptive action the alendronate is not improving bone strength and preventing fracture, and we consider using an anabolic agent; teriparatide. Clinical Cases in Mineral and Bone Metabolism 2017; 14(2):
2 R. Eastell et al. Duration of therapy In Europe, the Summary of Product Characteristics ( PAR_-_Product_Information/human/000425/WC pdf 15 January 2016) was changed to recommend The maximum total duration of treatment with Forsteo should be 24 months. The 24-month course of Forsteo should not be repeated over the patient s lifetime. This recommendation about not repeating the dose, is in part based on safety (see below) and in part based on efficacy, as a second course given after a gap of 12 months only results in about one-third of the effect on BMD and bone turnover markers as the first course (4). Some of the anabolic effects of teriparatide are not manifest until months 18-24, so to obtain maximum benefit from treatment it is important to complete the whole course (5). Safety The original phase 3 study of teriparatide (6) was planned for three years but had to be stopped after a median duration of 19 months as there were bone neoplasms noted in F344 rat studies. This effect of teriparatide in rats is dose and duration-dependent (7). In the Fracture Prevention Trial, there were no cases of osteosarcoma and the risk of cancer overall was lower in the treated than in the placebo group (6). The initial post-marketing surveillance in the US between 2003 to 2009 did not reveal any cases of osteosarcoma with teriparatide use, despite identifying 1448 cases of osteosarcoma. A recent review (5) described three cases of osteosarcoma diagnosed during teriparatide therapy, although one of these occurred in a man with prostate cancer with previous irradiation. Osteosarcoma is no more common in primary hyperparathyroidism than in the background population (8, 9) and in a cohort of 582 patients with primary hyperparathyroidism, none developed osteosarcoma (8). Osteosarcoma is more common in patients with Paget s disease of bone or those who have had radiation therapy and so teriparatide should not be used in these patients. There are several side effects that can be related to hypercalcaemia resulting from teriparatide treatment. These include nausea, dizziness, headache, leg cramps and arthralgia. Hypercalcaemia was reported in 11% patients in the Fracture Prevention Trial when the blood sample was taken within 6 hours of dosing. It is best practice to monitor serum calcium on treatment and if serum calcium is above normal to lower the dose of calcium supplementation or stop it. If the patient remains hypercalcaemic, the dosing frequency of teriparatide can be reduced to alternate days. In most patients, symptoms due to hypercalcaemia are mild and transient. There have been four reports of non-uraemic calciphylaxis (10), but the extreme rarity means that physicians just need to be aware of this possible complication. Efficacy Fracture risk The Fracture Prevention Trial included postmenopausal women with osteoporosis defined as at least two moderate atraumatic vertebral fractures, one moderate vertebral fracture and BMD T-score below -1.0, or two mild vertebral fractures and BMD T-score below The relative risk of new radiographic vertebral fracture in women treated with teriparatide 20mcg vs placebo was 0.35 (95% CI 0.22 to 0.55), and the relative risk of nonvertebral fragility fracture was 0.47 (95% CI 0.25 to 0.88). The number of hip fractures (four in the placebo group and two in the 20mcg group) was too small to draw any conclusions about hip fracture. In addition to the Fracture Prevention Trial, there have been two observational studies of teriparatide on fracture risk - Extended Forsteo Observational Study (ExFOS) (11) and Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) (12). These studies reported similar fracture risk reduction to the Fracture Prevention Trial; 75% reduction in clinical vertebral fractures and 49% reduction in all fractures in ExFOS, and 43 to 49% reduction in nonvertebral fractures in DANCE. There have been no studies comparing shorter term (18 months) with longer term (24 months) teriparatide therapy on fracture risk. However, both ExFOS and DANCE reported that the later phases of the 24-month course were associated with lower rates of non-vertebral fracture than the earlier phases. In the Fracture Prevention Trial, there appeared to be a greater effect on non-vertebral fractures beyond one year than before one year (6). Lindsay analysed these data further to show that for each month of treatment the hazard ratio of non-vertebral fracture decreased by 7% (13). Bone mineral density, geometry and bone strength One of the largest prospective studies of teriparatide is the European Forsteo Study or EUROFORS. In this trial, a 24- month course of teriparatide therapy was associated with a progressive increase in both lumbar spine and total hip BMD in treatment-naive patients (Figure 1). In patients on prior bisphosphonate, the increase at the total hip was not progressive as there was an early reduction in total hip BMD before the increase in the later months of treatment, particularly in those who were previously treated with alendronate or risedronate (14). Similar continued increases in BMD to 24 months have been reported in other studies (3, 15-17). Quantitative computed tomography allows the study of bone strength by applying finite element models. This has been used for the spine, and it showed a progressive improvement over 24 months (18) and for the total hip where it also showed a progressive improvement over 24 months (19). Whitmarsh (2016) (20) used hip QCT to show that cortical thickness increases and density decreases in response to TPTD and endocortical trabecular density increases; the latter was greater if the treatment was for 24 rather than 18 months. Bone turnover markers Several bone turnover markers have been studied for monitoring response to teriparatide. The procollagen I N propeptide, PINP has proven to have the greatest signal to noise ratio, and so it is the most suitable marker (21, 22). Bone formation markers increase within days of starting teriparatide and reach a peak between 6 and 12 months. They remain above baseline for the whole of the 24 month treatment period (15, 16). The markers even remain elevated in the setting of glucocorticoid-induced osteoporosis (3). The increase in PINP correlates with histological estimates of bone turnover by biopsy (15, 23, 24). Resorption markers increase later than formation markers, but also peak at Clinical Cases in Mineral and Bone Metabolism 2017; 14(2):
3 Teriparatide treatment of osteoporosis Figure 1 - EUROFORS Study: absolute BMD changes from baseline at the spine (A) and total hip (B). Numbers at the tops of the columns are the percent change from baseline. From Eastell (2009). Clinical Cases in Mineral and Bone Metabolism 2017; 14(2):
4 R. Eastell et al. Figure 2 - The effect one bone turnover markers of a two-year course of teriparatide treatment (mean 30 mcg daily) followed by a one-year break and then a one-year re-treatment at the same dose in men and women with osteoporosis (Finkelstein 2009). Note how there is a big increase in bone turnover during the first 12 months of treatment, then a decrease off treatment, but little increase with repeat treatment. months and remain above baseline throughout 24 months, consistent with ongoing remodelling (15). Bone histomorphometry There is an increase in bone formation rate after giving teriparatide. This is due to both an increase in the work of the cells (mineral apposition rate) and the number of the cells (mineralising surfaces as a proportion of total surfaces), and this was observed over a 24-month period for endocortical, intracortical and periosteal surfaces of the cortex (Ma 2014). There is an increase in both of these measures of bone formation by 6 months, and on most surfaces this increase persists to 24 months of treatment (25). What happens after teriparatide therapy is stopped? There are only two randomised controlled trials that allow study of the BMD effect of stopping teriparatide treatment compared to changing to another active drug and both used raloxifene. In one study (26), teriparatide was given for one year, and patients randomised to a further year of teriparatide, or a year of raloxifene or no active treatment and they gained a further 3.6%, no change, or lost 2.8% at the spine, respectively. In the other study (27), teriparatide was given for one year, and patients randomised to a year of raloxifene, or placebo and they lost 2.2% and 4.4% at the spine, respectively. The expected rate of bone loss in untreated postmenopausal women is 0.5 to 1.0% per year, so bone loss is accelerated when teriparatide is stopped. The Fracture Prevention Trial was followed by an observational period during which patients could select to take bisphosphonates or take nothing over 18 months, and they gained about 3% or lost about 3% at the spine, respectively (28). This observational data in women is supported by observational data in men showing that bisphosphonates can prevent bone loss after stopping teriparatide (29, 30). There is also evidence that denosumab (31) and oestrogen (32) prevent bone loss after stopping teriparatide. Thus, accelerated bone loss after teriparatide treatment can be reduced to some extent by raloxifene. Follow-on treatment with bisphosphonates and denosumab prevent bone loss and may achieve further small increases in BMD. Therefore it is usually recommended in clinical practice to follow a course of teriparatide with an anti-resorptive drug. There is not yet evidence to determine how long this follow-on treatment should be continued. What is the effect of a repeated course of teriparatide? There is only one study that addresses this question. Finkelstein (2009) (4) administered an average dose of 30 mcg daily to men and women with osteoporosis for two years, gave a one year gap, then re-treated at the same dose for one year. They found that during the two-year period the anabolic effect assessed by bone turnover markers began to wane, as is usually observed and that there is very little biochemical response to a second period (Figure 2). Cosman treated patients with cyclical teriparatide three months on and three months off over 24 months and patients receiving this regime had significantly less BMD gain at 24 months compared with continuous daily treatment (33). Mechanisms of apparent resistance Why does teriparatide have less of an anabolic effect in the second year as compared to the first year of treatment and why is there little benefit from re-treatment? The apparent refractory nature of the bone to continued or repeated treatment could be due to the production of antibodies to teriparatide, but these have never been observed. There could be receptor downregulation as with repeated exposure to other hormones, or there may be a depletion of bone cell precursors. Why is there accelerated bone loss after stopping treatment? We don t know the answer to any of these questions. Frost (2003) (34) proposed that when drugs are stopped then bone density should return to the baseline value as there is disuse-mode remodelling. He didn t use this mechanism to explain apparent resistance although it is possible that this could be the mechanism. We don t know how the changes in remodelling postulated by the mechanostat theory are mediated. One idea that has been proposed is 176 Clinical Cases in Mineral and Bone Metabolism 2017; 14(2):
5 Teriparatide treatment of osteoporosis that during teriparatide therapy there is an increase in Dickopf-1 (35), a negative regulator of bone formation, acting through the Wnt pathway. Its levels increase, particularly during the second year of teriparatide treatment and so could mediate an apparent resistance. Combination treatment There is evidence to suggest that teriparatide could achieve greater BMD increases in simultaneous combination treatment with anti-resorptives. Teriparatide combined with zoledronic acid or denosumab increases BMD more than teriparatide alone (16, 36). Over 24 months, spine BMD increased 12.9% with denosumab and teriparatide, 9.5% with teriparatide alone and 8.3% with denosumab alone. In the cyclical study, women treated with cyclical teriparatide and alendronate had similar BMD gain to women treated with continuous teriparatide, despite only receiving half the dose of teriparatide (33). However, in other studies co-treatment with alendronate attenuated the BMD increase compared with teriparatide alone, so there may be some complexities in the interaction of alendronate and teriparatide (37, 38). Although combined treatment may achieve greater BMD gain, there are no fracture data to show that the combination has greater anti-fracture efficacy than single agent treatment. References 1. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18(11): Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1): Saag KG, Zanchetta JR, Devogelaer J-P, et al. Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial. Arthritis and Rheumatism. 2009;60(11): Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009;94(7): Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016;27(8): Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19): Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhpth(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32(4): Jimenez C, Yang Y, Kim HW, et al. Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res. 2005;20(9): Cinamon U, Turcotte RE. Primary hyperparathyroidism and malignancy: studies by nature. Bone. 2006;39(2): Monegal A, Peris P, Alsina M, Colmenero J, Guanabens N. Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment. Osteoporos Int. 2016;27(8): Langdahl BL, Ljunggren O, Benhamou CL, et al. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int. 2016;99(3): Beall DP, Feldman RG, Gordon ML, et al. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study. Osteoporos Int. 2016;27(3): Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(6): Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3): Stepan JJ, Burr DB, Li J, et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int. 2010;21(12): Leder BZ, Tsai JN, Uihlein AV, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2014;99(5): Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone. 2010;47(3): Graeff C, Chevalier Y, Charlebois M, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res. 2009;24(10): Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res. 2010;25(3): Whitmarsh T, Treece GM, Gee AH, Poole KE. The Effects on the Femoral Cortex of a 24 Month Treatment Compared to an 18 Month Treatment with Teriparatide: A Multi-Trial Retrospective Analysis. PloS one. 2016;11(2):e Eastell R, Krege J, Chen P, Glass E, Reginster J. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Current Medical Research and Opinion. 2006;22(1): Krege JH, Lane NE, Harris JM, Miller PD. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25(9): Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24(8): Dempster DW, Zhou H, Recker RR, et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2012;97(8): Dempster DW, Cosman F, Zhou H, Nieves JW, Bostrom M, Lindsay R. Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. J Bone Miner Res. 2016;31(8): Eastell R, Nickelsen T, Marin F, et al. Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS). Journal of Bone and Mineral Research. 2009;24(4): Adami S, San Martin J, Munoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hpth(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008;19(1): Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18): Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004;15(12): Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on ver- Clinical Cases in Mineral and Bone Metabolism 2017; 14(2):
6 R. Eastell et al. tebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5): Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. The Lancet. 2015;386 (9999): Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001;16(5): Cosman F, Nieves JW, Zion M, et al. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. The Journal of clinical endocrinology and metabolism. 2015;100(7): Frost HM. Bone s mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol. 2003;275(2): Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. The Journal of clinical endocrinology and metabolism. 2011; 96(5): Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhpth(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3): Finkelstein JS, Leder BZ, Burnett SA, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006;91(8): Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95(4): Clinical Cases in Mineral and Bone Metabolism 2017; 14(2):
Forteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationTeriparatide for osteoporosis: importance of the full course
Osteoporos Int (2016) 27:2395 2410 DOI 10.1007/s00198-016-3534-6 REVIEW Teriparatide for osteoporosis: importance of the full course R. Lindsay 1 & J. H. Krege 2 & F. Marin 3 & L. Jin 2 & J. J. Stepan
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationTreatment of Osteoporosis: Unmet Needs and Emerging Solutions
J Bone Metab 2018;25(3):133-140 https://doi.org/10.11005/jbm.2018.25.3.133 pissn 2287-6375 eissn 2287-7029 Review Article Treatment of Osteoporosis: Unmet Needs and Emerging Solutions Bente Lomholt Langdahl,
More informationTristan Whitmarsh 1*, Graham M. Treece 1, Andrew H. Gee 1, Kenneth E. S. Poole 2
Mapping bone changes at the proximal femoral cortex of postmenopausal women in response to alendronate and teriparatide alone, combined or sequentially Tristan Whitmarsh 1*, Graham M. Treece 1, Andrew
More informationIn women who have not been on prior osteoporosis
CLINICAL TRIALS JBMR Hip and Spine Strength Effects of Adding Versus Switching to Teriparatide in Postmenopausal Women With Osteoporosis Treated With Prior Alendronate or Raloxifene Felicia Cosman, 1,2
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationTeriparatide in the management of osteoporosis
REVIEW Teriparatide in the management of osteoporosis Donald Bodenner Carolyn Redman Ann Riggs Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA Abstract: Fracture
More informationEffects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
Accepted Manuscript Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis Adolfo Díez-Pérez, Fernando Marin, Erik F. Eriksen, David
More informationRecombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
CURRENT DRUG THERAPY CHAD DEAL, MD* Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic JAMES GIDEON, MD, PhD Blanchard Valley
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationFactors related to bone forming inadequate response to treatment (teriparatide/pth 1-84) in patients with severe osteoporosis. Preliminary results
ORIGINALS / Rev Osteoporos Metab Miner 2015 7;4:85-90 85 Gifre L 1, Monegal A 1, Filella X 2, Muxi A 3, Guañabens N 1, Peris P 1 1 Unidad de Patología Metabólica Ósea - Servicio de Reumatología - Hospital
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationRecombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis
Ulster Med J 2013;82(2):89-93 Paper Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis Thomas McNeilly, Colette McNally, Michael Finch, Timothy Beringer
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationEffective Health Care
Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic
More informationEndocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni. Hot topics in osteoporosis. How long to treat
Endocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni Hot topics in osteoporosis How long to treat Dott. Bruno Madeo bruno.madeo@unimore.it www.endocrinologia.unimore.it/on-line/home.html
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationSCIENTIFIC DISCUSSION. London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011
SCIENTIFIC DISCUSSION London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011 TABLE OF CONTENTS I. INTRODUCTION... 3 II. CLINICAL ASPECTS... 4 2.1 Clinical pharmacology... 4 2.2
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationOSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION
V O L U M E 5 6 N U M B E R 2 J U N E 2 0 1 4 OSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION PANMINERVA MED 2014;56:97-114 J. Y., A. NEUPREZ, CH. BEAUDART, F. BUCKINX, J. SLOMIAN,
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationAlthough osteoporosis therapy has advanced substantially
REVIEW Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy Benjamin Z Leder 1,2 1 Harvard Medical School, Boston MA, USA 2 Endocrine Unit, Massachusetts General Hospital,
More informationParathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials
Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials Longxiang Shen, Xuetao Xie, Yan Su, Congfeng Luo, Changqing
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationjournal of medicine The new england One Year of Alendronate after One Year of Parathyroid Hormone (1 84) for Osteoporosis abstract
The new england journal of medicine established in 112 august 11, 25 vol. 353 no. 6 One Year of Alendronate after One Year of Parathyroid Hormone (1 ) for Osteoporosis Dennis M. Black, Ph.D., John P. Bilezikian,
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationAnabolic Therapy With Teriparatide Indications Beyond Osteoporosis
Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis Andreas Panagopoulos MD, PhD Upper Limb & Sports Medicine Orthopaedic Surgeon Assistant Professor, University of Patras Outline Teriparatide
More informationORIGINAL INVESTIGATION
Parathyroid Hormone for Treatment of Osteoporosis Carolyn Crandall, MD ORIGINAL INVESTIGATION Background: Osteoporosis is a common condition associated with multiple deleterious consequences. No therapy
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More information1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationReview Article Efficacy and safety of denosumab and teriparatide treatment for osteoporosis: a systematic review and meta-analysis
Int J Clin Exp Med 2017;10(4):5949-5956 www.ijcem.com /ISSN:1940-5901/IJCEM0048218 Review Article Efficacy and safety of denosumab and teriparatide treatment for osteoporosis: a systematic review and meta-analysis
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationHead-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis
ORIGINAL RESEARCH Chun-Lin Liu, MD 1,3, Han-Chung Lee, MD 1,3 Chun-Chung Chen, MD 1,4, Der-Yang Cho, MD 1,2,3 1Department of Neurosurgery, Neuropsychiatric Center, China Medical University Hospital, 2Graduate
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationThis is a repository copy of Microarchitecture of bone predicts fractures in older women.
This is a repository copy of Microarchitecture of bone predicts fractures in older women. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/130351/ Version: Accepted Version
More informationRenata Caudarella. Fondazione Ettore Sansavini per la Ricerca Scientifica (Health Science Foundation ) - GVM Care & Research
Renata Caudarella Fondazione Ettore Sansavini per la Ricerca Scientifica (Health Science Foundation ) - GVM Care & Research Introduc/on During the past two decades, many randomized controlled trials (RCTs)
More informationCIC Edizioni Internazionali. Bone quality and bone strength: benefits of the bone-forming approach. Mini-review
Bone quality and bone strength: benefits of the bone-forming approach Giovanni Iolascon Laura Frizzi Gioconda Di Pietro Annarita Capaldo Fabrizio Luciano Francesca Gimigliano Department of Medical and
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationInfluence of remodeling on the mineralization of bone tissue
Influence of remodeling on the mineralization of bone tissue G. Boivin, D. Farlay, Y. Bala, A. Doublier, P.J. Meunier, P.D. Delmas INSERM Unité 831, Université de Lyon, Lyon, France. Short Title : Bone
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationParathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
0163-769X/05/$20.00/0 Endocrine Reviews 26(5):688 703 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/er.2004-0006 Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis:
More informationRecent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationForteo (Teriparatide) AHM
Forteo (Teriparatide) AHM Clinical Indications Forteo (Teriparatide) is considered medically necessary if criteria are met for any 1 or more of the following Treatment of post-menopausal women with osteoporosis
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationTymlos (abaloparatide) NEW PRODUCT SLIDESHOW
Tymlos (abaloparatide) NEW PRODUCT SLIDESHOW Introduction Brand name: Tymlos Generic name: Abaloparatide Pharmacological class: Human parathyroid hormone related peptide analog Strength and Formulation:
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationOsteoporosis is a skeletal disorder characterized by decreased
REVIEW Influence of Dosing Interval and Administration on the Bone Metabolism, Skeletal Effects, and Clinical Efficacy of Parathyroid Hormone in Treating Osteoporosis: A Narrative Review Kyoung Min Kim,
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More information